Long-term (1 year) acceptability of perindopril in type II diabetic patients with hypertension.
This study is aimed at assessing long-term efficacy and tolerance of a newly developed angiotensin-converting-enzyme (ACE) inhibitor, perindopril, in type II diabetics. After 1 month of placebo (T0), perindopril was given for 12 months (T12) to 17 hypertensive type II diabetics, treated either by insulin, sulfonylurea, and/or biguanide. Supine diastolic blood pressure was normalized (less than or equal to 90 mm Hg) in 12 (67%) and 15 patients (83%) at 1 and 12 months, respectively. Glycemic control remained unchanged throughout the study. No significant changes occurred in creatinine clearance. The lipid profile showed an improvement with a significant increase in high density lipoprotein cholesterol without any modification in weight (difference not significant). We conclude that perindopril normalized blood pressure and improved the lipid profile without affecting glycemic control nor renal function during long-term treatment in hypertensive type II diabetic patients.
Jandrain
B
B
I.M.S. Hornu, Belgium.
Herbaut
C
C
Depoorter
J C
JC
Voorde
K V
KV
D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D007211:Indoles / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D020913:Perindopril; D013997:Time Factors
D000806:Angiotensin-Converting Enzyme Inhibitors; D007211:Indoles; D008055:Lipids; D020913:Perindopril